search for




 

Medication-Related Osteonecrosis of the Jaws: A Literature Review
J Oral Med Pain 2022;47:1-9
Published online March 30, 2022;  https://doi.org/10.14476/jomp.2022.47.1.1
© 2022 Korean Academy of Orofacial Pain and Oral Medicine

Gyeong-Mi Kim, Seong-Yong Moon, Jae-Seek You, Gyeong-Yun Kim, Ji-Su Oh

Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University, Gwangju, Korea
Correspondence to: Ji-Su Oh
Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University, 309 Pilmun-daero, Dong-gu, Gwangju 61452, Korea
Tel: +82-62-230-3813
Fax: +82-62-222-3810
E-mail: jsoh@chosun.ac.kr
https://orcid.org/0000-0002-8369-5025
Received March 2, 2022; Revised March 21, 2022; Accepted March 22, 2022.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of antiresorptive agents and bone-modifying agents. It is of the utmost importance to know the management of the MRONJ to improve the patient’s quality of life. This study comprehensively reviews the current definitions of MRONJs, and antiresorptive medications, clinical manifestation and staging, risk factors, treatment strategies, and prevention methods of MRONJ. The disease is defined as an exposure of bone and osteonecrosis of the jaw in the oral cavity for at least 8 weeks in patients taking antiresorptive drugs or antiangiogenic agents and with no history of radiotherapy treatment of the jaws. Many articles have reported risk factors associated with MRONJ such as systemic diseases, antiresorptive medication, oral infection, and poor oral hygiene. Osteonecrosis and antiresorptive medications including bisphosphonate and denosumab have been strongly associated, but the pathology of MRONJ is only limited. Hence, an effective and appropriate management and treatment for MRONJ is still to be defined. The objectives of MRONJ treatment are to minimize osteonecrosis and relieve symptoms, and many treatments are suggested from conservative treatment to marginal resection, but this remains controversial. Appropriate treatment of MRONJ remained difficult, although many studies are being covered.
Keywords : Bisphosphonate; Denosumab; Jaw; Osteoporosis; Romosozumab
INTRODUCTION

Recently, it has been reported that the number of patients with medication-related osteonecrosis of the jaws (MRONJs) is increasing [1]. The most debated side-effects of antiresorptive medication is MRONJ [2,3], including bisphosphonate-related osteonecrosis of the jaw (BRONJ) [4] and denosumab-related osteonecrosis of the jaw [5,6]. The American Association of Oral and Maxillofacial Surgeons (AAOMS) change the term MRONJ at 2014 in effort of increasing number of osteonecrosis cases with other antiresorptive (e.g., denosumab) and antiangiogenic therapies which the diagnostic criteria for MRONJ are based on clinical, radiographic features and pharmacological history [2]. In 2021, The Korean Association of Oral and Maxillofacial Surgeons (KAOMS) and the Korean Society for Bone and Mineral Research (KSBMR) had proposed the localized guideline customized for the local Korean situation on MRONJ [7]. In 2022, the AAOMS revisions in treatment strategies highlighted current research status [8]. Especially since the position paper was published in 2022 AAOMS after 8 years, the new position paper is required to compare the 2014 AAOMS position paper with the 2021 KAOMS and KSBMR paper to investigate the latest trend of MRONJ.

A patient with lesions on the maxillofacial region can be diagnosed with MRONJ if the following criteria are satisfied: (1) Current or past use of antiresorptive or antiangiogenic agents; (2) Exposure of the jaw bone or intraoral or extraoral fistula persisting for more than 8 weeks; (3) No history of head and neck radiation therapy [7]. The disease worsens oral hygiene, increasing morbidity, inducing an adverse effect on quality of life, and interrupts ideal dental treatment [7,9]. It is important to establish the precise mechanisms and treatment strategies of MRONJ. Available clinical information about when to perform dental treatments in osteoporosis patients and other agents important to prevent developing MRONJ [1] are to be discovered. Although MRONJ is induced by the various drugs, taking antiresorptive medications as a treatment for osteoporosis induces the high incidence of MRONJ in particular. Hence, this paper focuses on the effect of antiresorptive drugs prescribed in osteoporosis. This paper reviews the definitions of MRONJ, and antiresorptive medications, clinical manifestation and staging, risk factors, treatment strategies, and prevention methods of MRONJ.

ANTIRESORPTIVE MEDICATIONS

Generally, some medical conditions cause abnormal osteoclast activity [10,11]. Antiresorptive medications are currently considered the treatment in patients with osteoclastic bone disease to decrease bone turnover as these medications improve bone density and bone quality [12]. Antiresorptive medications are commonly prescribed for the benefits of stopping the progression of osteoporosis [10-12]. The prior antiresorptive drugs are bisphosphonate and denosumab, which have the most dominant effect in MRONJ.

Bisphosphonate is a dominantly effected to developing MRONJ, it is most famous antiresorptive medication taking either orally or intravenously. It targets osteoclasts and interrupts their function [12]. Since its powerful effect in inhibiting osteoclastic activity by increasing bone density and reducing the remodeling process, the quality of life in most patients is given to the decreased risk of osteoporotic fractures [2]. However, MRONJ results from taking antiresorptive medications with the occurrence of a significant downside risk [2,13]. Bisphosphonate can be use either nitrogen-containing bisphosphonates (alendronate, ibandronate, risedronate, and zoledronate) (Table 1) [2,14] or non-nitrogen-containing bisphosphonates (etidronate, tiludronate, and clodronate) [12]. The effect of medication appears within six hours. Since its powerful affinity to the bone, a long half-life of medication may last at least 10 years [13,15]. Bisphosphonate administration can be done orally and intravenously. Oral administration uptake shows only 1% absorbance into the gastrointestinal tract and intravenous (IV) shows an absorption rate of over 50% [16]. The prevalence of BRONJ in osteoporosis patients with the administration of bisphosphonates is known to range from 0% to 0.04%, and some papers show a prevalence of less than 0.001% [17,18]. The prevalence of BRONJ with the administration of bisphosphonates for more than 2 years is known to range from 0.05% to 0.21% and seems to be related to the duration of the bone exposure [19].

Denosumab is newly released antiresorptive medication and administered by subcutaneous (SQ) injection. Denosumab plays a role as osteoprotegerin produced by osteoblasts which are induced in an anti-RANKL antibody [12]. It decreased bone resorption in disrupting osteoclast creation, differentiation, and existence [12]. Since the RANKL-inhibitors cannot be attached to the bone, unlike bisphosphonate, denosumab has a short half-life. As a result, the effects of denosumab in the bone do not last longer than that of bisphosphonate and generally decrease within six months of the last treatment [2].

Romosozumab is a new monoclonal antibody drug administered through SQ, that is used in osteoporotic women for prevention of fracture. Binding and inhibiting sclerostin via the Wnt pathway results in decreased bone resorption and increased bone formation. When exposed to romosozumab, the risk for development of MRONJ ranges from 0.03% to 0.05% [20]. Patients with romosozumab administration should be continuously monitored to assess a risk factor for MRONJ.

CLINICAL MANIFESTATION AND STAGING

An optimal and exquisite staging system founded on clinical features and radiographic findings is used for the diagnosis of MRONJ, which clinicians can provide suitable treatment strategies to patients with MRONJ [21]. The MRONJ staging system adopted by AAOMS was developed by Ruggiero et al. in 2006, then subsequently updated by the AAOMS in 2014 and 2022 (Table 2) [2,8,22,23]. The 50% of stage 0 of patients developed MRONJ, and the other 50% would not develop to clinically obvious MRONJ, thus the stage 0 has been under discussion [21]. In 2022, AAOMS defined the symptoms, clinical findings and radiographic findings of stage 0 of MRONJ [8].

Symptoms: (1) Odontalgia not explained by an odontogenic cause; (2) Dull, aching bone pain in the jaw, which may radiate to the temporomandibular joint region; (3) Sinus pain, which may be associated with inflammation and thickening of the maxillary sinus wall; (4) Altered neurosensory function. Clinical findings: (1) Loosening of teeth not explained by chronic periodontal disease; (2) Intra oral or extra oral swelling. Radiographic findings: (1) Alveolar bone loss or resorption not attributable to chronic periodontal disease; (2) Changes to trabecular pattern sclerotic bone and no new bone in extraction sockets; (3) Regions of osteosclerosis involving the alveolar bone and/or the surrounding basilar bone; (4) Thickening/obscuring of periodontal ligament (thickening of the lamina dura, sclerosis and decreased size of the periodontal ligament space) [24]. Radiographic parameters in estimated MRONJ were sclerosis, lytic changes, periosteal reaction and sequestration [25]. Typical characteristics of the radiography of MRONJ are in Fig. 1 and a radiographic of a patient with MRONJ symptoms is shown in Fig. 2.

RISK FACTOR

There are a lot of the risk factors that contributed to developing MRONJ. The risk factors can be classified in three themes: the type of medication, systemic risk factor, and a local risk factor (Table 3) [26]. The use of bisphosphonate, denosumab, and romosozumab are considered serious risk factors for development of MRONJ [1,24]. The risk of medication highly depends on the dosage, route, and intake duration after administration [2]. The risk of development of MRONJ is increases as the dose-time increasing [26].

Systemic risk factors for developing MRONJ involve cardiovascular disease (hyperlipidemia, angina, and hypertension), vitamin D deficiency, corticosteroid use, diabetes, osteomalacia, hypocalcemia, hypoparathyroidism, anemia, osteoporosis, renal dialysis, sarcoidosis, rheumatoid arthritis, Paget’s disease of bone, Sjögren’s syndrome, erythropoietin therapy, alcoholism, tobacco use, age, and obesity [2,26,27].

The most often reported risk factor for MRONJ is tooth extraction as the causative factor (52%-61%) [1,26,28]. The most known risk factor in developing MRONJ is existing periodontal infection of the patients with antiresorptive medication administration [24]. The acidity was increased by the infection, leading to suppression of the healing mechanism and resulting in osteonecrosis [12]. In this result, the bone of the jaw is susceptible from various infections compared to other sites of bones in the body [22]. Furthermore, when comparing bone necrosis sites affected by antiresorptive drugs, osteonecrosis occurs more in the mandible about 73% than in the maxilla about 22.5% [2]. Despite the biological mechanisms not exactly known, MRONJ arises more commonly in the mandible than maxilla. The mandible is susceptible to necrosis and infections due to the only single blood supply it has [2]. Moreover, acute dental infection, endodontic treatment, implant management (implant placement, bone augmentation, and peri-implantitis), periodontal disease, periodontal surgery, trauma occurred by unfitted dentures, anatomical factors (exostoses, torus, knife-edge ridge, and mylohyoid ridge), and other oral conditions (xerostomia, poor oral hygiene, and excessive bite force) have also been stated [2,26,27].

TREATMENT STRATEGIES FOR MEDICATION-RELATED OSTEONECROSIS OF THE JAWS

Treatment strategies are controversial because the scientific evidence for the pathogenesis of MRONJ is limited, and current treatment strategies are based on clinical symptoms rather than definitive criteria. Treatment strategies for MRONJ were established for each stage in the position paper between AAOMS in 2014 [2] and 2022 [8], and KAOMS and KSBMR in 2021 [7] (Table 4). The goal of treatment can be achieved to avoid infection, pain control, and the management of bone resorption and necrosis [24,26].

A patient with some symptoms without exposed bone should be carefully diagnosed as Stage 0, because it has been reported that about 50% of patients in Stage 0 have progressed to a higher stage (stage 1, 2, or 3) [27]. The patients with Stage 0 are recommended to symptomatic treatment (e.g., infection and pain control) and non-operative treatment. A close observation could allow early detection of the advance to an upper stage [2,27,29].

Non-operative therapy is recommended along with patient education, patients monitoring per 3 to 4 months, the rinsing with antimicrobial, and improving oral hygiene. Immediate operation is not required at stage 0 and 1, although minor surgical treatments such as removal of necrotic bone or sequestrectomy are recommended to remove the necrotic bone and reduce soft tissue trauma [2,29-31]. Non-operative treatment is provided for patients with at-risk stage or asymptomatic in early stages. This treatment could be executed to patients who cannot receive surgical therapy, though non-operative treatment only provides temporary relief of symptoms in about 70% of cases of early stage MRONJ patients [32]. It includes chlorhexidine mouthwash, antibiotic therapy, keeping good oral hygiene, and periodic clinical follow-up and it can minimally improve the state or stabilize the oral condition. The adjunctive treatments like low-intensity laser therapy, hyperbaric oxygen, and ozone therapy were reported in some studies with a higher success result through a combination therapy [33,34]. Among the adjunctive treatments, recombinant human parathyroid hormone (rhPTH, teriparatide) would be a promising therapeutic modality, while short-term teriparatide medication would be a good choice to impaired bone remodeling for MRONJ patients [35]. The administration of teriparatide improves the activity of osteoclasts and increases the number of osteoclasts which lesser osteocytes that are unable to survive and greater turnover of bone, then decreasing the chance of bone necrosis [36].

The stage 2 and 3 of MRONJ are tough to be distinguished clearly, then treatment strategies for stages 2 and 3 of MRONJ are not clear. Although there is insufficient clinical evidence that antibiotics are preferable to stage 2 of MRONJ, antimicrobial mouth rinsing and use of antibiotics for systemic antimicrobial control are recommended for patients with stage 2 [2,21,31]. A bacterial membrane is formed above exposed necrotic bone reported to interrupt the effect of antimicrobial treatment. Therefore, removal or debridement of the osteonecrosis area should be considered [37]. Follow-ups per 8 weeks and education to patients are also fulfilled focused on the guideline of MRONJ [21]. A surgical approach to exposed necrotic bone may be carried out, when conservative treatment results in dissatisfaction. Necrotic bone exposure state requires surgical approach with conservative or adjunctive treatment [33]. The surgical treatment is achieved through sequestrectomy of necrotic bone with antibiotic medication and antiseptic mouth rinsing, combined with adjunctive treatments like leukocyte-platelet rich fibrin and ozone therapy [34]. However, when conservative debridement method has failed and progressed to the advanced stage of MRONJ, segmental resection to the elimination of all necrotic bone and only leaving healthy bone is applied to osteonecrosis bone for obtaining pure, healthy bone [33,34,38].

In 2022, the position paper of AAOMS presented a treatment approach through algorithms to streamline the process of the evaluation and to improve management strategies for patients with MRONJ [8]. The strategies are based on a current review on non-operative treatment and operative treatment. It is acceptable for all stages based on judgment to surgical treatment and patient risk factors [8]. It was recommended that decisions on non-operative or operative treatment should be done under consideration of the specific situation of a patient and tailored to individual needs according to the size and location of the MRONJ. Radiographic imaging is important in evaluation of MRONJ lesions. Especially, cone beam computerized tomography image identifies forming or fully formed sequestrum and it helps to potentially minimize the surgical procedure [25,39]. Sometimes, segmental resection or marginal resection of the mandible and partial maxillectomy are effective operative methods [40,41], and this approach can be applied to patients with all stages of MRONJ, including Stage 1 lesion existing above the inferior alveolar nerve or inferior to the maxillary sinus floor [42]. MRONJ is a complex disease that should be performed operative treatment at the right time [41,43]. The management and treatment protocol for MRONJ is demanding and remains a controversial issue [13,15,28].

PREVENTION METHOD OF MEDICATION-RELATED OSTEONECROSIS OF THE JAWS

Prevention is essential in reducing the risk of MRONJ [10,11,32]. As a preventive measure, a thorough patient screening can significantly lower the risk of MRONJ outbreak [24]. To recognize an individual at risk stage and prevent dental infection are the dentist’s responsibility. It should be carried out through regular check-ups to maintain good oral hygiene [24]. Moreover, patients taking antiresorptive therapy should be examined clinically and radiographically in effort not to create any acute infections and to prevent possible symptoms [2,24].

A drug-holiday is a temporary terminated drug administration, having a drug-holiday prior to surgical treatment remains a controversial subject to minimize the risk of osteonecrosis [1]. Patients with a history or current antiresorptive drug use through an orally for less than four years have a low risk of development of MRONJ and requires no alteration in the planned procedure (e.g., surgical extraction or any other surgical treatments) [2]. However, the physician should be deciding drug holidays or possible dose alteration medication and patients should be announced about the risk of development of MRONJ. Patients with orally bisphosphonate administration more than four years or less than four years with combination use of corticosteroids and an antiangiogenic medication will be given a guideline as follows: the physician would suggest the withdrawal of bisphosphonate medication for at least two months before surgical treatment if the systemic condition of the patient allows a drug holiday, and it could last until the osseous and mucosal recovery [2].

One of the most serious risk factors is tooth extraction that develops MRONJ [2,31]. Recently, clinicians recommended starting dental treatment without discontinuation of bisphosphonate medications [29], although they previously recommended that endodontic treatment should be chosen rather than extraction of tooth in patients who receive bisphosphonates to IV [2]. Tooth extraction is done on patients with taking bisphosphonate, then the remaining sharp edges near tooth extraction area must be smoothened and extraction socket closure with mucoperiosteal flaps would be performed. Also, antibacterial medication should be administered after tooth extraction [29]. But there is limited correlation between users of denosumab and tooth extraction. Some clinical papers recommended without a drug holiday for invasive dental treatment including tooth extraction [21,29].

Implant placement, peri-implantitis, taking bisphosphonates after placement of dental implant, and removal of dental implants have been announced to trigger MRONJ in patients with osteoporosis [29,44]. The degrees of risk for development of MRONJ on implant treatment have not been exactly elucidated. The removal of dental implant would be the risk factors for development of MRONJ, then, patients taking bisphosphonates for osteoporosis with peri-implantitis should not easily consider implant removal [44]. Strict management programs like short-term intervals of follow-up, oral examinations of teeth and implants, taking radiographs to evaluate the implant, and cleaning of peri-implant are recommended.

CONCLUSION

Antiresorptive medications for treated osteoporosis have been strongly associated with MRONJ. An effective and appropriate management for MRONJ should be defined. Careful treatment planning with periodic and frequent follow-ups are recommended for preventing of MRONJ. In addition, minimally invasive surgical procedures are preferred, and evaluating the individual risk in each patient is very important.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

Figures
Fig. 1. Radiographic images of estimated medication-related osteonecrosis of the jaw. Examples of severity of sclerosis, lytic changes, periosteal reaction, and sequestration. Arrows indicate the radiographic feature assessed. Adapted from the article of Walton et al. (Dentomaxillofac Radiol 2019;48:20180128) [25].
Fig. 2. The osteolytic lesion is localized in the posterior of left mandible located at or below the inferior alveolar canal with the symptoms of pus discharge and mild pain with palpation on #35 to #37 buccal gingiva, and hypoesthesia on left lower lip and chin and aching bone pain in the left mandible area. A sagittal computed tomography view showing extensive bone destruction in the posterior of the mandible near the inferior alveolar canal. It scored stage 2 of medication-related osteonecrosis of the jaw and required antibiotic medication and sequestrectomy treatment. For symptom relief of hypoesthesia on the left lower lip and aching bone pain in the left mandible area, symptomatic treatment is also required.
Tables

Antiresorptive drugs for osteoporosis

Generic name Trade name Route Dose/schedule Relative potencya
Bisphosphonate
Alendronate Fosamax Oral 10 mg/day, 70 mg/wk 100-1,000
Ibandronate Boniva Oral 2.5 mg/day, 150 mg/mo 1,000-10,000
IV 3 mg/every 3 mo
Risedronate Actonel Oral 5 mg/day, 35 mg/wk 1,000-10,000
Zoledronate Zometa IV 5 mg/y >10,000
Reclast IV 5 mg/y
Denosumab Xgeva SQ 120 mg/4 wk Unknown
Prolia SQ 60 mg/6 mo
Romosozumab Evenity SQ 210 mg/mo Unknown

IV, intravenous; SQ, subcutaneous.

aThe antiresorptive potency of 1 assigned to etidronate and other bisphosphonates are measured relative to etidronate.

Data from the article of Ruggiero et al. (J Oral Maxillofac Surg 2014;72:1938-1956) [2]; Goodchild and Donaldson (Gen Dent 2018;66:23-26) [14].

Clinical conditions and imaging features by stage of MRONJ according to the AAOMS

MRONJ stage Clinical condition Imaging feature
At risk No apparent necrotic bone in patients treated with bone-modifying agents Nonspecific radiographic changes
Stage 0 No clinical evidence of necrotic bone, but nonspecific clinical findings and symptoms Alveolar bone loss or resorption, sclerotic alveolar bone, thickening and sclerosis of the lamina dura, Thickening or obscuring of the periodontal ligament
Stage 1 Exposed and necrotic bone or fistulas that probe to the bone in patients who are asymptomatic and have no evidence of infection May present same as stage 0, changes to trabecular pattern: disorganized, trabecular pattern and poor corticomedullary differentiation
Stage 2 Exposed and necrotic bone in patients with pain and clinical evidence of infection Mixed diffuse osteosclerosis, osteolysis from the alveolar bone to the jaw bone, thickening of the mandibular canal, periosteal response, maxillary sinusitis and sequestration
Stage 3 Exposed and necrotic bone or a fistula that probes to the bone in patients with pain, infection and one or more of the following: exposed and necrotic bone extending beyond the region of alveolar bone resulting in pathologic fracture, extraoral fistula, oral antral or oral-nasal communication or osteolysis extending to the inferior border of the mandible or sinus floor Osteosclerosis/osteolysis of the surrounding bone, pathologic mandibular fracture and osteolysis extending to the maxillary sinus floor

MRONJ, medication-related osteonecrosis of the jaw; AAOMS, American Association of Oral and Maxillofacial Surgeons.

Adapted from the article of He et al. (Int J Oral Sci 2020;12:30) [23].

Risk factors associated with osteonecrosis

Medication Bisphosphonate and denosumab
Duration of medication therapy (dose-time)
Systemic risk factor Systemic disease: cardiovascular disease (hyperlipidemia, angina, and hypertension), vitamin D deficiency, corticosteroid use, diabetes, osteomalacia, hypocalcemia, hypoparathyroidism, anemia, osteoporosis, renal dialysis, sarcoidosis, rheumatoid arthritis, Paget’s disease, Sjögren’s syndrome, erythropoietin therapy
Alcoholism, smoking, age, obesity
Local risk factor Dental or periodontal infection
Periodontal surgery
Endodontic treatment
Tooth extraction
Implant management: implant placement, peri-implantitis, bone augmentation
Trauma occurred by unfitting dentures
Anatomical factors: exostoses, torus, mylohyoid ridge, knife-edge ridge
Oral conditions: xerostomia, poor oral hygiene, and excessive bite force

Treatment strategies for MRONJ established by stage, compared position paper between AAOMS in 2014 and 2022, and KAOMS and KSBMR in 2021

Stage AAOMS (2014) [2] KAOMS and KSBMR (2021) [7] AAOMS (2022) [8]

Non-operative treatment Operative treatment
Stage 1 Mouth rinsing with antibacterial, clinical follow-ups per 3-4 months, patient education, assessment of indications for last bisphosphonate therapy Antibacterial oral rinsing, immediate surgery is not necessary Local wound care to exposed bone, antimicrobial rinsing, improved oral hygiene, sequestrectomy (mobile, well-formed sequestrum) Marginal resection (Mn; in case, located above neurovascular canal)
Alveolectomy (Mx; in case, located inferior to the sinus floor)
Stage 2 Taking antibiotics orally for symptomatic treatment, pain control, mouth rinsing with antibacterial, debridement for infection control and to relieve soft tissue irritation Antibacterial oral rinsing and antibiotics prescribe, pain control with analgesics, sequestrectomy that irritate the soft tissue Local wound care to exposed bone, antimicrobial rinsing, sequestrectomy (mobile, well-formed sequestrum), systemic antibiotics, pain control Segmental resection (Mn; in case, located below neurovascular canal in edentulous) Partial maxillectomy (Mx; in case, located superior to the sinus floor)
Stage 3 Mouth rinsing with antibacterial, pain control, antibiotic medication, debridement or surgical resection for longer term palliation of pain and infection Pain control, oral antibacterial rinsing, infection control through antibiotic treatment, surgical debridement or resection Local wound care to exposed bone, antimicrobial rinsing, sequestrectomy (mobile, well-formed sequestrum), systemic antibiotics (oral or intravenous), pain control Segmental resection (Mn)
Partial maxillectomy (Mx)

AAOMS, American Association of Oral and Maxillofacial Surgeons; KAOMS, Korean Association of Oral and Maxillofacial Surgeons; KSBMR, Korean Society for Bone and Mineral Research; Mn, mandible; Mx, maxilla.

References
  1. Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent 2021;7:47.
    Pubmed KoreaMed CrossRef
  2. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-1956. Erratum in: J Oral Maxillofac Surg 2015;73:1440. Erratum in: J Oral Maxillofac Surg 2015;73:1879.
    Pubmed CrossRef
  3. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3-23.
    Pubmed CrossRef
  4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117.
    Pubmed CrossRef
  5. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010;68:959-963.
    Pubmed KoreaMed CrossRef
  6. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010;48:221-223.
    Pubmed CrossRef
  7. Kim JW, Kwak MK, Han JJ, et al. Medication related osteonecrosis of the jaw: 2021 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2021;28:279-296.
    Pubmed KoreaMed CrossRef
  8. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaw-2022 update. J Oral Maxillofac Surg . doi: 10.1016/j.joms.2022.02.008. [Epub ahead of print].
    Pubmed CrossRef
  9. Miksad RA, Lai KC, Dodson TB, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 2011;16:121-132.
    Pubmed KoreaMed CrossRef
  10. Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Woo SB. Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol 2013;49:977-983.
    Pubmed CrossRef
  11. Voss PJ, Poxleitner P, Schmelzeisen R, Stricker A, Semper-Hogg W. Update MRONJ and perspectives of its treatment. J Stomatol Oral Maxillofac Surg 2017;118:232-235.
    Pubmed CrossRef
  12. Shibahara T. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 2019;247:75-86.
    Pubmed CrossRef
  13. Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int 2016;2016:8768162.
    Pubmed KoreaMed CrossRef
  14. Goodchild JH, Donaldson M. What do you really need to know about bisphosphonates? Gen Dent 2018;66:23-26.
    Pubmed
  15. Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E. Medication-related osteonecrosis of the jaw: surgical or non-surgical treatment? Oral Dis 2018;24:238-242.
    Pubmed CrossRef
  16. Kim HW, Lee MW, Lee JH, Kim MY. Comparison of the effect of oral versus intravenous bisphosphonate administration on osteoclastogenesis in advanced-stage medication-related osteonecrosis of the jaw patients. J Clin Med 2021;10:2988.
    Pubmed KoreaMed CrossRef
  17. Khan AA, Rios LP, Sándor GK, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 2011;38:1396-1402.
    Pubmed CrossRef
  18. Ulmner M, Jarnbring F, Törring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 2014;72:76-82.
    Pubmed CrossRef
  19. Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243-253.
    Pubmed CrossRef
  20. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017;377:1417-1427.
    Pubmed CrossRef
  21. Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 2019;37:2270-2290.
    Pubmed CrossRef
  22. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg 2009;67(5 Suppl):13-18.
    Pubmed CrossRef
  23. He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci 2020;12:30.
    Pubmed KoreaMed CrossRef
  24. Di Fede O, Panzarella V, Mauceri R, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018;2018:2684924.
    Pubmed KoreaMed CrossRef
  25. Walton K, Grogan TR, Eshaghzadeh E, et al. Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings. Dentomaxillofac Radiol 2019;48:20180128.
    Pubmed KoreaMed CrossRef
  26. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 2018;24:527-536.
    Pubmed CrossRef
  27. Khan AA, Morrison A, Kendler DL, et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom 2017;20:8-24.
    Pubmed CrossRef
  28. Kuroshima S, Sasaki M, Murata H, Sawase T. Medication-related osteonecrosis of the jaw-like lesions in rodents: a comprehensive systematic review and meta-analysis. Gerodontology 2019;36:313-324.
    Pubmed CrossRef
  29. Yoneda T, Hagino H, et al; Japanese Allied Committee on Osteonecrosis of the Jaw. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 2017;35:6-19. Erratum in: J Bone Miner Metab 2017;35:20.
    Pubmed CrossRef
  30. Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015;44:568-585.
    Pubmed CrossRef
  31. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2015;22:151-165.
    Pubmed KoreaMed CrossRef
  32. Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 2016;6:97-104.
    Pubmed KoreaMed CrossRef
  33. Agrillo A, Filiaci F, Ramieri V, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci 2012;16:1741-1747.
    Pubmed
  34. Kim JW, Kim SJ, Kim MR. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg 2014;52:854-859.
    Pubmed CrossRef
  35. Kwon YD, Kim DY. Role of teriparatide in medication-related osteonecrosis of the jaws (MRONJ). Dent J (Basel) 2016;4:41.
    Pubmed KoreaMed CrossRef
  36. Zushi Y, Takaoka K, Tamaoka J, Ueta M, Noguchi K, Kishimoto H. Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report. Int J Implant Dent 2017;3:11.
    Pubmed KoreaMed CrossRef
  37. Wanger G, Gorby Y, El-Naggar MY, et al. Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:71-78.
    Pubmed CrossRef
  38. Rodriguez-Lozano FJ, Oñate-Sánchez RE. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med Oral Patol Oral Cir Bucal 2016;21:e595-e600.
    Pubmed KoreaMed CrossRef
  39. Hadaya D, Soundia A, Freymiller E, et al. Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care. J Oral Maxillofac Surg 2018;76:2332-2339.
    Pubmed KoreaMed CrossRef
  40. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67:943-950.
    Pubmed CrossRef
  41. Carlson ER, Schlott BJ. Anti-resorptive osteonecrosis of the jaws: facts forgotten, questions answered, lessons learned. Oral Maxillofac Surg Clin North Am 2014;26:171-191.
    Pubmed CrossRef
  42. Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008;26:4634-4638.
    Pubmed CrossRef
  43. Park H, Copeland C, Henry S, Barbul A. Complex wounds and their management. Surg Clin North Am 2010;90:1181-1194.
    Pubmed CrossRef
  44. Yamamoto S, Maeda K, Kouchi I, et al. Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. J Oral Implantol 2018;44:359-364.
    Pubmed CrossRef